Skip to main content

Trudy G Oliver

Professor of Pharmacology and Cancer Biology
Pharmacology & Cancer Biology
Campus Box 3813, Durham, NC 27708
308 Research Drive, LSRC C138B, Durham, NC 27708

Selected Grants


NEUROD1 function in SCLC fate and plasticity

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2029

Coordinating Center for the NCI Small Cell Lung Cancer Research Consortium

ResearchPrincipal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2022 - 2027

Training Program in Developmental and Stem Cell Biology

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2001 - 2027

Otolaryngology Surgeon- Scientist career Path (OSSP) program

Inst. Training Prgm or CMEMentor · Awarded by National Institute on Deafness and Other Communication Disorders · 2022 - 2027

Mechanisms of Arginine Deprivation in Small Cell Lung Cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2026

NEUROD1 function in SCLC fate and plasticity

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2024 - 2029

Coordinating Center for the NCI Small Cell Lung Cancer Research Consortium

ResearchPrincipal Investigator · Awarded by Memorial Sloan-Kettering Cancer Center · 2022 - 2027

Training Program in Developmental and Stem Cell Biology

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2001 - 2027

Otolaryngology Surgeon- Scientist career Path (OSSP) program

Inst. Training Prgm or CMEMentor · Awarded by National Institute on Deafness and Other Communication Disorders · 2022 - 2027

Mechanisms of Arginine Deprivation in Small Cell Lung Cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2026

Cell and Molecular Biology Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2021 - 2026

Uncovering novel vulnerabilities to treat SCLC therapy resistance

ResearchCollaborator · Awarded by Lung Cancer Research Foundation · 2023 - 2025

Investigating and targeting metabolic vulnerabilities of MYC-driven small cell lung cancer

FellowshipPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

Pharmacological Sciences Training Grant

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2020 - 2025

Pro-tumor functions of neutrophils in squamous cell lung cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2025

Aur1959 inhibition in small cell lung cancer (SCLC)

ResearchPrincipal Investigator · Awarded by Auron Therapeutics · 2023 - 2024

SOX9 promotes a unique immunogenic state in small cell lung cancer (SCLC)

FellowshipPrincipal Investigator · Awarded by Lung Cancer Initiative of North Carolina · 2023 - 2024

Targeting SCLC plasticity with constellation pharmacology

ResearchPrincipal Investigator · Awarded by University of Utah · 2022 - 2023

Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung Cancer

ResearchPrincipal Investigator · Awarded by Washington University in St. Louis · 2022 - 2022

Fellowships, Gifts, and Supported Research


Investigating and targeting metabolic vulnerabilities of MYC-driven small cell lung cancer · September 2022 - August 2025 Mentor · National Institutes of Health Ireland, Abbie F31

External Relationships


  • American Association for Cancer Research
  • Auron Therapeutics
  • Feinberg School of Medicine Northwestern University
  • Fox Chase Cancer Center
  • Genes & Development
  • American Association for Cancer Research
  • Auron Therapeutics
  • Feinberg School of Medicine Northwestern University
  • Fox Chase Cancer Center
  • Genes & Development
  • Lung Cancer Research Foundation
  • Memorial Sloan Kettering Cancer Center
  • Moffit Cancer Center
  • Purdue University
  • US Patent
  • University of California Los Angeles
  • University of Pennsylvania
  • Vanderbilt University

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.